January 2022
Pharmacy and Therapeutics Committee Meeting Update
At the December 13, 2021 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed the medications below and decided the following:
| Name & Indication |
Decision |
| Orladeyo (berotralstat) – Indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. | Premium and Value formularies: Non-preferred specialty brand with prior authorization Core NH formulary: Medicare Advantage formulary: |
| Lupkynis (voclosporin) – Indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). | Premium and Value formularies: Remain Non-Formulary Core NH formulary: Medicare Advantage formulary: |
Publication Information
Audrey Kleinberg,
Director, Provider Relations & Communications
Annmarie Dadoly,
Editor
Joseph O’Riordan,
Writer
Kristin Edmonston,
Production Coordinator